Distributors give you coverage on day one, and a direct team gives you control. Here is what each channel means for your customer relationships, your data, and your compliance obligations.
Most device companies treat the channel question as a reach question: how many accounts can we cover, and how fast? That framing misses what actually changes hands. A medical device distribution strategy decides who owns the customer relationship, who sets the price the hospital sees, and who holds the data on what happens in the field. All three are hard to take back once you sign them away.
Hospitals are built to buy through distribution. About 90% of hospitals partner with commercial medical supply distributors for products and logistical support, a share that has held roughly steady for a decade.1 That explains the appeal for a launch-stage company. It does not tell you whether a distributor will sell a new device or simply move boxes for products that already have demand.
For a company near FDA clearance, the channel decision often arrives before the commercial plan is finished. A distributor offers coverage on day one, and a direct team costs money before it produces any. Both can be right, for different products and stages.
The following post breaks down the three kinds of partners that get called distributors, what a direct sales force buys you, where regulatory obligations follow your product into the channel, what belongs in a distributor agreement, and how to sequence a hybrid model.
The word covers at least three business models, and founders often compare them as if they were one. Each one changes who owns the account.
Before comparing terms, name which of these you are talking to. The channel choice in medical device distribution comes down to how much of the customer relationship you are willing to hand to another company.
A direct sales force gives a medical device company control over the four things that matter most at launch: the clinical message, user training, price, and data. Your reps say what your regulatory team approved. Your clinical specialists stand in the case. Every call, objection, and complaint lands in your own system.
That control is how you learn. A novel device usually has an unsettled sales motion at launch: which specialty champions it, which objection stalls it, and how long hospital approval takes. A direct team builds that knowledge inside your company, where it shapes the next hire and the next message.
The cost is fixed and front-loaded. Salary, travel, and samples arrive months before a territory produces predictable revenue. With limited runway, the real question is how many direct territories you can afford to run long enough to learn from.
Independent sales reps and specialty distributors earn their place when they already call on the people who buy your device. A rep who sees the same orthopedic surgeons every week, with products in an adjacent category, can open doors a new hire cannot. Coverage arrives without the fixed cost, and commission means you pay mostly when something sells.
The fit is strongest when the product is easy to explain, sits naturally in the rep's existing bag, and does not require a new clinical workflow. It is weakest when the device is novel, needs hands-on training, or competes for attention with higher-revenue products the rep already carries. A partner paid on volume will spend time where volume is easiest.
Ask every prospective partner which products in their bag earn the most commission, and where yours would rank. The answer tells you how much selling your device will get.
Selling through a partner does not move your obligations off your desk. It adds a second set of records you depend on.
FDA requires device distributors to maintain complaint records containing any communication that alleges deficiencies in a device's identity, quality, durability, reliability, safety, effectiveness, or performance. Those records must be kept for two years or the expected life of the device, whichever is longer.2 Your quality system still needs those complaints, so the handoff timeline belongs in writing.
If your device is subject to an FDA tracking order, distributors must promptly send you information such as device identifiers, receipt dates, and disposition, and must make those records available for your audit on written request.3 A partner without the systems to do this becomes your compliance gap.
The personal services safe harbor under the federal Anti-Kickback Statute protects agent compensation only when the method for setting it is fixed in advance, consistent with fair market value, and not determined in a way that takes into account the volume or value of federal health care program business.4 Percentage commissions are common in device sales, but they generally fall outside that safe harbor and are judged on their facts. Have healthcare counsel review the structure before you sign.
Most distributor agreements are drafted around territory and price. The terms that protect a launch-stage company are about information and exit.
We covered the data side of this in our post on MedTech revenue operations: companies that launch through distributors often lose visibility into their accounts entirely. The agreement is the one moment when you hold the bargaining position to prevent that.
A hybrid sales model in MedTech works best as a sequence rather than a permanent split. In launch work at Cicada, a MedTech launch partner, the pattern that holds up is to sell direct in a small number of anchor accounts first, then extend through partners once the sale is understood.
The direct phase produces what a partner needs to succeed: a tested clinical message, a training program, documented objections, early outcome data, and a realistic sense of how long hospital approval takes. We covered how those approvals work in our post on value analysis committee strategy. A partner handed a proven playbook, under an agreement that requires the same data and complaint reporting your direct territories use, has a far better chance than one asked to invent the sale.
Some products justify the reverse order. A simple device that fits an established call point may go to partners first, with a direct team added later for strategic accounts. Either way, write down which accounts are direct, which are partner-owned, and how each side is paid when they overlap.
It is the plan for how your device reaches customers and gets sold to them: through a direct sales force, independent agents, stocking distributors, or a combination. It determines who owns the customer relationship, who sets pricing, and who holds field data.
It depends on how complex the product is and how well it fits an existing call point. Novel devices that need clinical training usually benefit from a direct team early. Simple products that fit a rep's existing bag can work well through partners.
A stocking distributor buys your product, takes title, and resells it at its own price. An independent sales rep sells on your behalf for a commission without taking title, so the customer buys directly from you.
Yes. Device distributors must maintain complaint records, and for devices under an FDA tracking order they must report tracking information to the manufacturer. The manufacturer keeps its own quality and reporting obligations.
Beyond territory and price, it should cover account-level sales reporting, a complaint handoff timeline, control of training and marketing materials, exclusivity tied to performance, and transition rights on termination.
A medical device distribution strategy is usually discussed as coverage math. In practice it decides who owns the customer, the price, and the field data, and those decisions are expensive to reverse once an agreement is signed.
Decide which accounts you need to learn from directly, write your data and complaint requirements down before you talk to partners, and treat every agreement as part of your launch infrastructure. If you want help building that plan, see how we do it.
Related reading: MedTech Revenue Operations: Why Your CRM Is Launch Infrastructure
Cicada is a MedTech launch partner that helps FDA-cleared companies bridge the gap between clearance and commercial success. Through market access messaging, KOL engagement programs, operational support, brand development, and precision-driven market expansion, Cicada aligns marketing, sales, and operations to build revenue-ready healthcare companies. Learn more at cicada.co or see how we do it.
1 Health Industry Distributors Association. "Majority of Hospital Systems Utilize Commercial Distribution." June 2026. https://www.hida.org/KnowledgeCenter/KnowledgeCenter/articles/majority-hospital-systems-utilize-commercial-distribution.aspx
2 Electronic Code of Federal Regulations. "21 CFR 803.18, What Are the Requirements for Establishing and Maintaining MDR Files or Records That Apply to Me?" Accessed October 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-803/subpart-A/section-803.18
3 Electronic Code of Federal Regulations. "21 CFR 821.30, Tracking Obligations of Persons Other Than Device Manufacturers: Distributor Requirements." Accessed October 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-821
4 Electronic Code of Federal Regulations. "42 CFR 1001.952(d), Personal Services and Management Contracts and Outcomes-Based Payment Arrangements." Accessed October 2026. https://www.ecfr.gov/current/title-42/chapter-V/subchapter-B/part-1001/subpart-C/section-1001.952
We work with commercially-viable health technology companies that are ready to scale. If that sounds like you, let's talk.
Schedule a Call